Sarepta Therapeutics(DE:AB3A)
€16.62+0.00 (+2.34%)
DE:AB3A
Sarepta Therapeutics stock forecast
€16.62
At close:+0.00 (+2.34%)
Sarepta Therapeutics (AB3A) Stock Forecast & Price Target
6 Followers
AB3A Analyst Ratings
Hold
3Buy11Hold4Sell
Based on 18 analysts giving stock ratings to Sarepta Therapeutics in the past 3 months
AB3A Stock 12 Month Forecast
Average Price Target
EUR 19.19▲(15.45% Upside)Based on 18 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is EUR 19.19 with a high forecast of EUR 33.86 and a low forecast of EUR 4.46. The average price target represents a 15.45% change from the last price of EUR 16.62.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 33.86
AverageEUR 19.19
LowEUR 4.46
Highest Price TargetHighestEUR 33.86Average Price TargetEUR 19.19Lowest Price TargetLowestEUR 4.46
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| David Hoang | Deutsche Bank | EUR 16.04 | hold | -3.50%Downside | Upgraded | 11/10/26 | ||
| Eliana Merle | Barclays | EUR 17.82 | hold | 7.23%Upside | Reiterated | 11/09/26 | ||
| Yigal Nochomovitz | Citi | EUR 11.58 | sell | -30.30%Downside | Reiterated | 11/09/26 | ||
| Brian Skorney | Robert W. Baird | EUR 17.82→EUR 16.04 | hold | -3.50%Downside | Reiterated | 11/06/26 | ||
| Mitchell Kapoor | H.C. Wainwright | EUR 4.46 | sell | -73.19%Downside | Reiterated | 11/06/26 | ||
| Biren Amin | Piper Sandler | EUR 17.82 | hold | 7.23%Upside | Reiterated | 11/06/26 | ||
| Yanan Zhu | Wells Fargo | EUR 33.86 | buy | 103.73%Upside | Reiterated | 11/06/26 | ||
| Kostas Biliouris | Oppenheimer | EUR 31.19 | buy | 87.64%Upside | Reiterated | 11/06/26 | ||
| Yun Zhong | Wedbush | EUR 31.19 | buy | 87.64%Upside | Reiterated | 11/06/26 | ||
| Michael Ulz | Morgan Stanley | EUR 22.28 | hold | 34.03%Upside | Assigned | 11/06/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | sell | ― | Reiterated | 11/06/26 | ||
| Brian Abrahams | RBC Capital | EUR 15.15→EUR 16.04 | hold | -3.50%Downside | Reiterated | 11/05/26 | ||
| Kristen Kluska | Cantor Fitzgerald | EUR 18.71 | hold | 12.59%Upside | Reiterated | 11/05/26 | ||
| Ritu Baral | TD Cowen | EUR 15.15 | hold | -8.86%Downside | Reiterated | 10/21/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | EUR 17.82 | hold | 7.23%Upside | Reiterated | 10/15/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| David HoangDeutsche Bank | HoldUpgradedEUR 16.04 | 11/10/26 | -3.50%Downside | ||
| Eliana MerleBarclays | HoldReiteratedEUR 17.82 | 11/09/26 | 7.23%Upside | ||
| Yigal NochomovitzCiti | SellReiteratedEUR 11.58 | 11/09/26 | -30.30%Downside | ||
| Brian SkorneyRobert W. Baird | HoldReiteratedEUR 17.82→EUR 16.04 | 11/06/26 | -3.50%Downside | ||
| Mitchell KapoorH.C. Wainwright | SellReiteratedEUR 4.46 | 11/06/26 | -73.19%Downside | ||
| Biren AminPiper Sandler | HoldReiteratedEUR 17.82 | 11/06/26 | 7.23%Upside | ||
| Yanan ZhuWells Fargo | BuyReiteratedEUR 33.86 | 11/06/26 | 103.73%Upside | ||
| Kostas BiliourisOppenheimer | BuyReiteratedEUR 31.19 | 11/06/26 | 87.64%Upside | ||
| Yun ZhongWedbush | BuyReiteratedEUR 31.19 | 11/06/26 | 87.64%Upside | ||
| Michael UlzMorgan Stanley | HoldAssignedEUR 22.28 | 11/06/26 | 34.03%Upside | ||
| Tazeen AhmadBank of America Securities | SellReiterated | 11/06/26 | ― | ||
| Brian AbrahamsRBC Capital | HoldReiteratedEUR 15.15→EUR 16.04 | 11/05/26 | -3.50%Downside | ||
| Kristen KluskaCantor Fitzgerald | HoldReiteratedEUR 18.71 | 11/05/26 | 12.59%Upside | ||
| Ritu BaralTD Cowen | HoldReiteratedEUR 15.15 | 10/21/26 | -8.86%Downside | ||
| Unknown AnalystLeerink PartnersNot Ranked | HoldReiteratedEUR 17.82 | 10/15/26 | 7.23%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Sarepta Therapeutics
3 Months
Success Rate14/19 ratings generated profit
74%
Average Return
+10.84%
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +10.84% per trade.
1 Year
Success Rate14/19 ratings generated profit
74%
Average Return
+18.58%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +18.58% per trade.
2 Years
Success Rate14/19 ratings generated profit
74%
Average Return
+18.07%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 73.68% of your transactions generating a profit, with an average return of +18.07% per trade.
AB3A Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 8 | 8 |
| Buy | 2 | 1 | 1 | 0 | 0 |
| Hold | 13 | 13 | 15 | 17 | 17 |
| Sell | 4 | 4 | 6 | 5 | 6 |
| Strong Sell | 3 | 3 | 4 | 5 | 5 |
| total | 28 | 26 | 32 | 35 | 36 |
In the current month, AB3A has received 8 Buy Ratings, 17 Hold Ratings, and 11 Sell Ratings. AB3A average Analyst price target in the past 3 months is 19.19.
AB3A Financial Forecast
HighEUR 0.18
ConsensusEUR -0.28
LowEUR -1.40
AB3A Earnings Forecast
Next quarter’s earnings estimate for AB3A is -EUR 0.28 with a range of -EUR 1.40 to EUR 0.18. The previous quarter’s EPS was -EUR 0.24. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 349M
ConsensusEUR 317M
LowEUR 270M
AB3A Sales Forecast
Next quarter’s sales forecast for AB3A is EUR 317.24M with a range of EUR 269.73M to EUR 349.06M. The previous quarter’s sales results were EUR 342.00M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
AB3A Stock Forecast FAQ
What is DE:AB3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is €19.19.
What is DE:AB3A’s upside potential, based on the analysts’ average price target?
Sarepta Therapeutics has 15.45% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sarepta Therapeutics a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Hold, which is based on 3 buy ratings, 11 hold ratings and 4 sell ratings.
What is Sarepta Therapeutics’s share price target?
The average share price target for Sarepta Therapeutics is €19.19. This is based on 18 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €33.86, and the lowest forecast is €4.46. The average share price target represents a 15.45% increase from the current price of €16.62.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Street analysts.
How can I buy shares of Sarepta Therapeutics?
To buy shares of DE:AB3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
